IntroductIon
A critical care physician often has to manage patients who either present with or develop coagulation abnormalities in intensive care unit, and they are a predictor of both, the need for massive transfusion and mortality. 1 These abnormalities can range from something as simple as isolated thrombocytopenia to more complex multisystem coagulation defects. Table 1 shows the common causes of coagulopathy in critically ill patients. Moreover, in critically ill patients, assessing bleeding risk is one of the key management strategies to minimize any procedural or perioperative bleeding. Critically ill patients can be prone to bleeding for a wide variety of reasons including hereditary or acquired bleeding disorders (platelet function abnormalities, factor deficiencies and factor inhibitors), underlying medical conditions such as hepatic or renal disease and concomitant anticoagulation medications. Besides, certain connective tissue disorders can impact on the integrity of blood vessels, which make them more prone to bruising/bleeding. 
understandIng normal HemostasIs
Hemostasis is a complex process and involves multiple steps ( Fig. 1 ). It is subdivided into four phases. The first phase of primary hemostasis involves vasoconstriction and platelet plug formation and is triggered when the subendothelial collagen is
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exposed after vessel wall injury. This leads to platelet adhesion to the subendothelial layer via von Willebrand and glycoprotein Ib and subsequent platelet aggregation. Next comes secondary hemostasis, which involves the activation of coagulation factors and thrombin formation. Phase 3 requires fibrin clot formation and stabilization, and the final step requires inhibition of thrombin generation and fibrinolysis. Traditionally, this process has thought to occur via three pathways. The intrinsic pathway (uses factors VIII, IX, XI, XII), extrinsic pathway (uses factor VII), and common pathway where both converge to activate factor X (uses factors II, V, fibrinogen). In the new proposed coagulation cascade, this complete process does not occur continuously but instead requires three consecutive phases: namely, an initial phase, an amplification phase and the propagation phase. The liver is responsible for the production of most of the factors, namely; I, II, V, VII, VII, IX, X, XI, XIII and protein C (FXIV) and protein S. Thus, patients with advanced liver disease often have coagulopathy. The coagulation system also has a negative feedback mechanism to prevent overcoagulation and thrombosis. Thrombin also acts by activating plasminogen (to plasmin, which is an active enzyme in fibrinolysis) and stimulating the production of antithrombin (which decreases the production of thrombin and decreases the output of FXa).
evaluatIng coagulatIon
The most obvious indications that a patient has coagulopathy are an unusual drop in hemoglobin or persistent bleeding. This often manifests as the presence of ecchymosis, petechiae, haematuria, hematomas or prolonged bleeding from puncture sites. Excessive bleeding from surgical drains or incision sites may also occur. If the bleeding is significant and allowed to continue, it may lead to hypovolemic shock, hypoperfusion and organ failure. Apart from above physical signs of bleeding, one should also look for jaundice, splenomegaly, arthropathy, joint and skin laxity (Marfans or Ehlers-Danlos syndrome) as signs of systemic or connective tissue disorder. The other causes of easy bruising like alcohol abuse, purpura simplex, Cushing's disease, vitamin C deficiency should also be screened for. One should also take a detailed medication history to check if the patient is taking medications such as antiplatelet agents, anticoagulants (warfarin or NOVACs) and complementary medications that affect coagulation. Drugs like cephalosporins, ginkgo-biloba, interferon, SSRI, TCA are rare causes that can cause bleeding and bruising. 3 The screening tests for hemostasis are summarized in Table 2 . Despite their limitations, both prothrombin time (PT) and activated partial thromboplastin time (aPTT) remain the most common screening test to evaluate coagulation. PT measures the integrity of extrinsic and common pathway while aPTT measures the integrity of the intrinsic and common pathway. They assess the time it takes for both the pathways to generate cellular plasma and thus only investigate a narrow part of the coagulation system. Figure 2 highlights the factors involved in each pathway. These tests are designed for clinical monitoring of anticoagulation and not coagulopathy and thus only serve as useful starting points of investigation of coagulation. Mixing studies are done to determine whether a prolonged PT or aPTT or both are affected by the presence of a factor deficiency or a factor inhibitor. If the test normalises when plasma is added, it is due to factor deficiency, and if not, it is secondary to the presence of an inhibitor like lupus anticoagulant. These tests should accompany a detailed history, including medication and clinical examination. It is also essential to get the peripheral smear examination as it also helps in looking at the morphology of platelets and also identify systemic illness and other hematological disorders. Table 3 highlights the causes of abnormality in these tests and Table 4 highlights the defect associated with the use of anticoagulants.
Evaluation of Preexisting Coagulation Disorder
The British Committee for Standards in hematology and various Anesthesiology Society guidelines for perioperative assessment recommend evaluation of bleeding risk before surgery or invasive procedures for all patients. [4] [5] [6] Bleeding assessment tools (BATs) were developed to offer a simple, structured screening tool to improve the diagnostic accuracy of bleeding disorder with symptom severity, minimise investigations, predict the risk of bleeding and inform about the treatment strategies ( Table 5) .
It is easy to diagnose major bleeding disorders like hemophilia and vWD but challenging to diagnose or classify some of the mild bleeding disorders. In a prospective Indian study, Kotru et al. reported that of the 164 patients who presented with slight bleeding, epistaxis was the most common presentation with cutaneous bleeding, the next common site. A family history of bleeding was present in only 11 patients. Only 25% of the patients were confirmed to have a bleeding disorder based on the investigation, and the rest labeled as unclassified bleeding disorder. 7 Indian Journal of Critical Care Medicine, September 2019;23 (Suppl 3)
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Reversal of Coagulopathy
When managing a patient with coagulopathy, it is essential to consult a hematologist. It is also crucial to monitor the response to the treatment given by checking targeted tests. One can correct the factor deficiencies using fresh frozen plasma (FFP) when the coagulopathy is undifferentiated or secondary to causes like severe sepsis and DIC. Factor concentrates are used when one knows the coagulopathy is secondary to specific factor deficiency and or anticoagulant (e.g. warfarin). Table 6 highlights the advantages and disadvantages of each. 10 Plasma transfusion may be useful in a patient who requires volume resuscitation along with multiple factors to correct the coagulopathy (e.g. patients with trauma and or one with massive exsanguination). It is also important to maintain temperature >35 o C, ionized calcium levels >1.1 mmol/L and pH >7.25 in these patients. One also needs to activate a systematic transfusion therapy with local massive transfusion protocol to improve the delivery of blood products (packed blood cells, fresh frozen plasma, platelets in fixed ratios along with cryoprecipitate if the fibrinogen is <2.0 g/L). One gram of tranexamic acid followed by an infusion of 1 gram over 8 hours is also used in such scenarios. FFP is effective in correcting high PT as it has a dilution factor secondary to the volume. However, it is uncertain that prophylactically correcting INR decreases the incidence of bleeding. The TOPIC trial, which was an RCT, failed to show that transfusion of FFP (12 mL/kg) to correct the INR (>1.5-3.0) prevented bleeding complications in patients undergoing central venous catheter placement, percutaneous tracheostomy, chest tube or abscess drainage. 11 The amount of FFP needed to increase the desired level of factor concentration also varies. Chowdary et al. found that one may need volume as high as 30 mL/kg to achieve the target. 12 The common risks associated with FFP transfusion are transfusion-related acute lung injury (TRALI), transfusion-related circulatory overload, allergic or anaphylactic reactions. The less frequent complications include risk of transmission of infections, febrile nonhemolytic reactions, hemolytic reactions and red blood cell (RBC) alloimmunization. Factor concentrate therapy (Table 7) guided by viscoelastic testing (TEG or ROTEM) has been tried to minimize the use of blood products in patients undergoing major surgery and trauma but the benefits of this approach has not been demonstrated in big multicentre randomized control trials (RCT). 13, 14 Prothrombin complex concentrate (PCC) has variable concentrates of 4 factors, namely II, VII, IX, and X and are mainly approved for reversal of coagulopathy secondary to vitamin K antagonist. They are also used in the prevention and treatment of bleeding in patients with hemophilia B. Certain PCC also contain small levels of activated FVII. When compared to FFP, PCCs reverse INR faster and are easier to administer as do not need crossmatching. In scenarios when the INR is not corrected post PCC infusion, one should treat the patient with FFP.
Recombinant coagulation products are proteins which are now more readily available for managing bleeding patients on anticoagulants or with specific coagulation deficiencies. These proteins can be modified and can be used in patients with acquired antibodies and inhibitors to various factors. Recombinant activated factor VIIa is approved for patients with hemophilia with inhibitors but increasingly used in patients with life-threatening massive hemorrhage where conventional blood component therapy is unsuccessful. It only works once hypothermia, hypocalcemia, acidosis are corrected, and PT/aPTT optimized. Its significant side-effects are thromboembolic complications. Inactivated-zhzo recombinant FXa (Andexxa) has recently been approved for reversal of the anticoagulation effect of direct FXa inhibitors (apixaban and rivaroxaban). The limitation of this product is that the anticoagulant effect lasts while the infusion is ongoing (2 hours) and its high costs.
Factor XIII plays a vital role in the final step of clot formation and stabilization. Many studies have shown a reduction in factor FXIII in patients put on cardiopulmonary bypass and FXIII replacement, along with antifibrinolytic therapy reduces the risk of postoperative bleeding and in patients with major trauma. 15, 16 However, the presence alpha-2 antiplasmin protein (which inactivates plasmin) and other clotting factors (VIII, XIII, vWF) in addition to fibrinogen in the cryoprecipitate makes them more effective in terms of their duration and mode of action when compared to factor FXIII concentrates.
In the event when the coagulopathy is secondary to anticoagulants, it is ideal first to use specific anticoagulation reversing agents and it is also necessary to consult a haematologist. Table 8 highlights the specific reversal agents of various anticoagulants. 17 summary Coagulopathy is common in intensive care and can be multifactorial. It is crucial to find the underlying cause and understand the limitations of various tests to assess them. Early hematology referral is vital. FFPs remain the broad-spectrum therapy to correct coagulopathy. 
Contd…
